MRIMath
MRIMath is a healthcare technology company that specializes in AI-powered solutions for brain tumor segmentation and analysis. Their products, including the Cyber Device and AI-Based Segmentation tools, are designed to enhance clinical workflows and improve patient outcomes in neuro-oncology. With FDA approval for their Cyber Device, MRIMath is positioned as a leader in the market, offering innovative solutions that streamline complex treatment planning and provide accurate measurements for glioblastoma management. Their business model includes software as a service (SaaS) and collaborative tools for healthcare professionals, making them a valuable partner in the medical field.
MRIMath
MRIMath is a healthcare technology company that specializes in AI-powered solutions for brain tumor segmentation and analysis. Their products, including the Cyber Device and AI-Based Segmentation tools, are designed to enhance clinical workflows and improve patient outcomes in neuro-oncology. With FDA approval for their Cyber Device, MRIMath is positioned as a leader in the market, offering innovative solutions that streamline complex treatment planning and provide accurate measurements for glioblastoma management. Their business model includes software as a service (SaaS) and collaborative tools for healthcare professionals, making them a valuable partner in the medical field.
TL;DR
Headquarters: Birmingham, Alabama, USA
Core product: AI-powered MRI segmentation and volumetric analysis for brain tumors
Regulatory milestone: FDA-cleared Cyber Device (product referenced as Cyber Device)
Team size: ~24 employees
Recent funding: Grant disclosed Mar 26, 2023
Company Overview
Problem Domain
Neuro-oncology imaging workflows: tumor segmentation, volumetrics, treatment planning, and clinical collaboration.
Industry
Healthcare technology / Medical AI
Funding Track Record
Grant disclosed on March 26, 2023
Seed round disclosed
Grant disclosed
Investor Signal
“Includes grant and seed support from Innovate Alabama, Rowan University, National Institutes of Health (NIH), and gbeta”